Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech...
Transcript of Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech...
![Page 1: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/1.jpg)
Formulation of biotech products
Bruno Gander, PhD
Institute of Pharmaceutical Sciences,
ETH Zürich, Switzerland
![Page 2: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/2.jpg)
Acknowlegedments
![Page 3: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/3.jpg)
Statement of conflict
• None
![Page 4: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/4.jpg)
Learning objectives and outcomes
1) Knowledge of measures to remove microbial
contaminants and their limitations
2) Knowledge of conventional measures to
inhibit drug degradation and their limitations
3) Knowledge of newer approaches for protein
stabilization and improving protein delivery
![Page 5: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/5.jpg)
Challenges of biotech drugs
Antigenicity
Clearance
by MPS
Targeting
Presystemic
metabolism Half-life
Sustained action
Physical stability
Chemical stability
Bioavailability
Delivery kinetics Administration
routes
Sterilization
Biopharmaceuticals have lengthy, expensive and complicated formulation
processes in comparison to those of low molecular weight drugs
![Page 6: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/6.jpg)
Formulation strategies and tools
Microneedles
Bioadhesion
Protease
inhibitors
Aseptic
processing
Nasal delivery
Localized Delivery
PEGylation
Stabilization
Pulmonary delivery
Bioconjugation
Absorption
enhancers
Crystallization
![Page 7: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/7.jpg)
Sterility/purity of a biotech
product – the challenges
• Chemical and physical instability of drug
• Bacterial contaminants
• Viral contaminants (from production cell line or
process-related)
• Pyrogens (from production or process-related)
![Page 8: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/8.jpg)
Elimination and killing of
bacteria (yeast)
• Sterilization?
• Aseptic processing – sterile filtration (0.22 mm)
• Low protein binding filters, eg, hydrophilic PVDF, PES
rhHG filtration through 0.22 mm filters
PES Mixed Cellulose-esters
Nylon
PVDF
http://www.edenbiodesign.com/documents/
info_eden_biodesign1.pdf Maa and Hsu. J PharmSci 1998;87:808–812
![Page 9: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/9.jpg)
Elimination and killing of viruses
• Sources: cell banks, human/animal materials (plasma);
viral seeds; culture media; affinity matrices
• Aim: load of 10-6; 1 - 2 validated clearance steps
• Inactivation (preferred): heat, chemical
• Clearance:
- precipitation
- chromatography
- ultracentrifugation
- filtration
http://www.plasbumin.com/images/table_3.gif
![Page 10: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/10.jpg)
Virus clearance by filtration
• Size exclusion
and/or
adsorptive retention
• Direct flow or
tangential flow
Kern G and Krishnan M. Biopharm Int Oct 2006 http://www.edenbiodesign.com/
documents/info_eden_biodesign1.pdf
![Page 11: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/11.jpg)
Pyrogen removal
• Maximum endotoxin levels: 5 EU/kg product/h
• Detection: - rabbit - LAL - monocyte activation/cytokine assay
• Removal: - ion exchange chromtaography - ultrafiltration - inactivation (heat, oxidation, hydrolysis)
www.bact.wisc.edu/
themicrobialworld/endo1.jpg
![Page 12: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/12.jpg)
Instability of protein requires
extensive protein analytics
Purity - RP-HPLC; GPC - SDS-PAGE - FFF - Immunoblot - Endotoxin assay - Virus test - DNA assay
Concentration - Protein assay (Lowry) - UV, fluorescence - Amino acid quantitation - ELISA
Shape - CD - X-Ray
Activity - Bioassay - Specific binding assay
Structure/Sequence - N- and C- terminal - Amino acid analysis - Peptide mapping/ sequencing - Carbohydrate analysis - MS
Size - Electrophoresis - GPC - FFF - Light scattering - Ultrafiltration
Charge - IEF - IEC
Identity - Peptide mapping - IEF
![Page 13: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/13.jpg)
Additives needed to produce
water-soluble injectable solutions • pH
• Buffers
• Antioxidants
• Preservatives
• Surfactants
• H-bonding promoters
• Steric shields
• Complexation agents
• Cryoprotectants
• (Chemical stabilization)
4-6
Citrate, acetate, glycine, histidine, succinate,
phosphate, tris
Ascorbic acid, citric acid, Met, Cys, EDTA (O2
removal/protection; protection against light)
Phenol, benzyl alcohol, benzoic acid, parabens
Polysorbate, poloxamer, albumin
Sugars, glycols
PVP, dextran, PEG, albumin, poloxamer
Zn, Mg
Sugars, sugar alcohols, glass forming agents
(Pegylation, replacement of amino acids)
![Page 14: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/14.jpg)
Formulation development
Protein drug
candidate
In vivo
data
Preformulation
data Initial
formulation
Major degradation routes (stability studies)
Aggregation Deamidation Oxidation Aspartate
reaction
Thiol-disulfide
exchange
Stabilizers, lyophilization
Shelf-life
> 1-2y
Final
formulation
![Page 15: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/15.jpg)
Chemical and physical stability –
stress factors and effects
• Deamidation (Asn, Gln)
• Cleavage (Asp-X)
• Oxidation (Met, Cys, His, Trp, Tyr)
• Thiol disulfide exchange (Cys)
• Conformational changes
• Aggregation
• Adsorption
• pH
• Ionic strength
• Temp, O2
• Agitation, shear forces Stirring, pumping, filtration, filling
• Interfaces
• Freezing
• Freeze-drying
• Moisture
![Page 16: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/16.jpg)
Formulation?
Illustrated by Leigh Rondano,
Boehringer Ingelheim Pharmaceuticals
Intuition ? or Experimental factorial design?
Pfister L. PhD-thesis, ETH Zurich, 2007
![Page 17: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/17.jpg)
Effect of pH on solubility
of TGF-b3
Buffer pH
2 4 6 8 10 12
mg
/mL
TG
F-b
3
0
20
40
60
80
Solubility
Jen AH et al. J Control Rel 2001;78:25–34
![Page 18: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/18.jpg)
Effect of pH on sCT degradation
Lee KC et al. Pharm Res 1992;9:1521–1522
Degradation of salmon calcitonin in
0.01 M citric acid / 0.02 M phosphate
and in 0.01 M HCl / 0.02 M borate
buffer (pH 9) solution at 70 °C
![Page 19: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/19.jpg)
Effect of shaking on stability and
antigenicity of various insulins
Hinds and Kim. ADDR 2002;54:505–530
Antigenicity (Relative IgG-titres
in mice; %)
100.0
1.18
0
0.96
![Page 20: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/20.jpg)
Effect of shearing on aggregation
of proteins
Maa and Hsu. J Pharm Sci 87:808–812 (1998)
in presence of air-liquid interface;
Key: ○ rhGH; □ rhDNAse; ◊ rt-PA
in presence of 1% PS beads (4-150 mm)
Key: (●) rhGH; (○) rhGH + 0.05%
polysorbate 20; (□) rhDNAse; (◊) rt-PA
Protein monomer content under shearing (concentric cylinder device; 1500 rpm)
![Page 21: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/21.jpg)
Shelf-life of marketed
sCT products
Product Adminis-
tration
Storage Excipients
Miacalcin®
Novartis
sc, im 2-8 °C,
2 w at
RT
Acetate buffer, phenol
Forcaltonin®
Unigene
sc, im 2-8 °C Acetate buffer
Miacalcin®
Novartis
Nasal spray 15-25
°C for 4
w
HCl, benzalkonium
chloride
Fortical®
Unigen
Nasal spray 20-25
°C for
30 d
Citrate buffer, phenyl
ethyl alcohol, benzyl
alcohol, polysorbate 80
![Page 22: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/22.jpg)
Freeze-drying may increase
protein stability – critical steps
• Freezing
structural perturbations (‘cold denaturation’)
pH-shifts
increasing concentration of protein and additives
protein adsorption to ice-liquid interface
mechanical stress
• Dehydration structural perturbations (loss of H-bonds; unfolding)
structural damage (aggregation)
![Page 23: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/23.jpg)
Freeze-drying – excipients
• Buffering agents
• Antioxidants
• Surfactants
• Complexation agents
• Chelators
• Preservatives
• Tonicifiers
• Cryo-/lyoprotectants: PEG, sugars, mannitol, lactose,
trehalose, albumin
• Bulking agents: mannitol, sorbitol, glycine, arginine
• Collapse temp. modifiers: dextran, albumin, gelatine
![Page 24: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/24.jpg)
Cryo-/lyoprotectants, bulking agents,
collapse temperature modifiers
• Cryo-/lyoprotectants:
- replace water for hydrogen bonding
- increase Tg and collapse T of cake (cave sorbitol!)
- adsorb moisture from stoppers
- prevent overdrying during secondary drying step
- 350–500 moles of sugar/mole protein
• Bulking agents: elegance of cake
• Collapse temp. modifiers: increase collapse temperature
![Page 25: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/25.jpg)
Storage conditions for lyophilized
FDA-approved proteins
70%
at 2–
8°C
27%
at 15–
25°C
3%
at -20°C
![Page 26: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/26.jpg)
Example: trastuzumab
(Herceptin®)
• Recombinant humanized monoclonal antibody against HER2/neu receptor of tumor cells
• Lyophilisate • Components:
histidin HCl/histidin, trehalose, polysorbate 20
• Storage: 2–8 °C
• Incompatibilities: glucose, other drugs aggregation
• pH after reconstitution: 6
• Reconstitution: avoid shaking and foam formation
• Injection: empty syringe slowly to avoid aggregation
![Page 27: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/27.jpg)
New approaches for protein
stabilization (and controlled release)
Luginbuehl V et al. Eur J Pharm Biopharm
2004;58:197–208
![Page 28: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/28.jpg)
Adsorption on nanocarriers
Activity of soy bean
peroxidase exposed to
95°C.
(○) enzyme in solution
enzyme adsorbed on
nanocarriers:
(●) fullerenes;
(■) carbon nanotubes;
(▲) graphite flakes;
Asuri P et al. J Nanosci Nanotechnol 2007;7:1675–1678
![Page 29: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/29.jpg)
VEGF-polyelectrolyte nanoparticles
Bioactive VEGF in medium from human umbilical vascular endothelial cells (HUVEC) after incubation of (●)VEGF solution, or VEGF-polyelectrolyte nanoparticles: (○) dextran sulfate-chitosan; (△) dextran sulfate -polyethyleneimine; (□) dextran polyethyleneimine
Huang M et al. Biomacromolecules
2007;8:1607–1614
![Page 30: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/30.jpg)
Nasal spray of insulin (Exubera®)
Components
Insulin, 1 mg
Mannitol
Glycin
Na-citrat
NaOH
![Page 31: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/31.jpg)
Pulmonal inhalation
pulmozyme (rhDNAse; dornase-a)
• Inhalation solution (2.5 mg protein +CaCl2 +NaCl; not
buffered!; 2.5 ml WFI)
• Incompatibilities: other drugs or excipients
• Storage: 2–8°C; at 30°C for max. 24 h)
![Page 32: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/32.jpg)
Have we met the
learning objectives?
![Page 33: Formulation of biotech products - European Association of ...NXP).pdf · Formulation of biotech products Bruno Gander, PhD Institute of Pharmaceutical Sciences, ETH Zürich, Switzerland](https://reader030.fdocuments.in/reader030/viewer/2022040700/5d52762988c993ee5b8bddf8/html5/thumbnails/33.jpg)
ETH Zurich –
a world full of proteins and more!